Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.74 |
| ▸ | NPC1 | O15118 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10280292 | 0.86 | LMNA (0.75) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL880456 | 0.86 | KMT2A (0.64) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL880276 | 0.85 | LMNA (1.00) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL880296 | 0.85 | KMT2A (0.74) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL852839 | 0.85 | KMT2A (1.00) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL10280720 | 0.85 | KMT2A (0.74) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL853892 | 0.82 | KMT2A (0.69) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL12162833 | 0.82 | KMT2A (0.69) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL880347 | 0.82 | LMNA (1.00) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL7156373 | 0.77 | ALDH1A1 (0.58) | KMT2ANPC1MEN1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166553-A1 | ANTIMETASTATIC COMPOUNDS | UNIV BRIGHAM YOUNG (US) | 2016-06-16 | — | — | US | disclosed |
| US-20130158035-A1 | ANTIMETASTATIC COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2012027392-A2 | ANTIMETASTATIC COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158035-A1 | ANTIMETASTATIC COMPOUNDS | MET, HGFAC, HGF | KMT2A 3928/4885NPC1 1073/4885MEN1 391/4885 |
| US-20160166553-A1 | ANTIMETASTATIC COMPOUNDS | MET, HGFAC, HGF | KMT2A 3928/4885NPC1 1073/4885MEN1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.